Real-World Outcomes of Incurable Cancer Patients Treated with Unlisted Anticancer Treatments in an Academic Center in Quebec, Canada
Medical oncology is a rapidly evolving field, with new medications being discovered yearly, contributing to increased survival rates. However, accessing drugs in a timely manner can be challenging. In Quebec, Canada, a physician can prescribe an unlisted anticancer treatment through a regulated path...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-10-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/31/10/440 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850205118358618112 |
|---|---|
| author | Adam Miller Francois Panet Victoria Korsos Wilson H. Miller Gerald Batist |
| author_facet | Adam Miller Francois Panet Victoria Korsos Wilson H. Miller Gerald Batist |
| author_sort | Adam Miller |
| collection | DOAJ |
| description | Medical oncology is a rapidly evolving field, with new medications being discovered yearly, contributing to increased survival rates. However, accessing drugs in a timely manner can be challenging. In Quebec, Canada, a physician can prescribe an unlisted anticancer treatment through a regulated pathway under exceptional circumstances. We conducted a quality improvement study describing the outcomes of incurable cancer patients receiving unlisted anticancer therapy at the Jewish General Hospital between 2018 and 2019. Though our study did not include a comparator arm, unlisted anticancer therapies were associated with interesting median progression-free survival (11 months) and overall survival (25 months). Moreover, a large proportion of treatments, 44%, were subsequently reimbursed in the province of Quebec. Given the delay in anticancer drug reimbursement, this pathway is essential for timely access to oncology drugs. Such ‘special access’ programs will likely become increasingly important as precision medicine becomes the standard of practice. |
| format | Article |
| id | doaj-art-9e2b0a11236342128a8ec77e893d37ec |
| institution | OA Journals |
| issn | 1198-0052 1718-7729 |
| language | English |
| publishDate | 2024-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj-art-9e2b0a11236342128a8ec77e893d37ec2025-08-20T02:11:09ZengMDPI AGCurrent Oncology1198-00521718-77292024-10-0131105908591810.3390/curroncol31100440Real-World Outcomes of Incurable Cancer Patients Treated with Unlisted Anticancer Treatments in an Academic Center in Quebec, CanadaAdam Miller0Francois Panet1Victoria Korsos2Wilson H. Miller3Gerald Batist4Department of Medical Oncology, Queen’s University, Kingston, ON K7L 3N6, CanadaJewish General Hospital Segal Cancer Center, Montreal, QC H3T 1E2, CanadaDepartment of Hematology, Jewish General Hospital, Montreal, QC H3T 1E2, CanadaJewish General Hospital Segal Cancer Center, Montreal, QC H3T 1E2, CanadaJewish General Hospital Segal Cancer Center, Montreal, QC H3T 1E2, CanadaMedical oncology is a rapidly evolving field, with new medications being discovered yearly, contributing to increased survival rates. However, accessing drugs in a timely manner can be challenging. In Quebec, Canada, a physician can prescribe an unlisted anticancer treatment through a regulated pathway under exceptional circumstances. We conducted a quality improvement study describing the outcomes of incurable cancer patients receiving unlisted anticancer therapy at the Jewish General Hospital between 2018 and 2019. Though our study did not include a comparator arm, unlisted anticancer therapies were associated with interesting median progression-free survival (11 months) and overall survival (25 months). Moreover, a large proportion of treatments, 44%, were subsequently reimbursed in the province of Quebec. Given the delay in anticancer drug reimbursement, this pathway is essential for timely access to oncology drugs. Such ‘special access’ programs will likely become increasingly important as precision medicine becomes the standard of practice.https://www.mdpi.com/1718-7729/31/10/440QuebecCanadian Agency for Drugs and Technologies in Health (CADTH)Institut national d’excellence en santé et services sociaux (INESSS)incurable cancerunlisted medicationsdrug approval |
| spellingShingle | Adam Miller Francois Panet Victoria Korsos Wilson H. Miller Gerald Batist Real-World Outcomes of Incurable Cancer Patients Treated with Unlisted Anticancer Treatments in an Academic Center in Quebec, Canada Current Oncology Quebec Canadian Agency for Drugs and Technologies in Health (CADTH) Institut national d’excellence en santé et services sociaux (INESSS) incurable cancer unlisted medications drug approval |
| title | Real-World Outcomes of Incurable Cancer Patients Treated with Unlisted Anticancer Treatments in an Academic Center in Quebec, Canada |
| title_full | Real-World Outcomes of Incurable Cancer Patients Treated with Unlisted Anticancer Treatments in an Academic Center in Quebec, Canada |
| title_fullStr | Real-World Outcomes of Incurable Cancer Patients Treated with Unlisted Anticancer Treatments in an Academic Center in Quebec, Canada |
| title_full_unstemmed | Real-World Outcomes of Incurable Cancer Patients Treated with Unlisted Anticancer Treatments in an Academic Center in Quebec, Canada |
| title_short | Real-World Outcomes of Incurable Cancer Patients Treated with Unlisted Anticancer Treatments in an Academic Center in Quebec, Canada |
| title_sort | real world outcomes of incurable cancer patients treated with unlisted anticancer treatments in an academic center in quebec canada |
| topic | Quebec Canadian Agency for Drugs and Technologies in Health (CADTH) Institut national d’excellence en santé et services sociaux (INESSS) incurable cancer unlisted medications drug approval |
| url | https://www.mdpi.com/1718-7729/31/10/440 |
| work_keys_str_mv | AT adammiller realworldoutcomesofincurablecancerpatientstreatedwithunlistedanticancertreatmentsinanacademiccenterinquebeccanada AT francoispanet realworldoutcomesofincurablecancerpatientstreatedwithunlistedanticancertreatmentsinanacademiccenterinquebeccanada AT victoriakorsos realworldoutcomesofincurablecancerpatientstreatedwithunlistedanticancertreatmentsinanacademiccenterinquebeccanada AT wilsonhmiller realworldoutcomesofincurablecancerpatientstreatedwithunlistedanticancertreatmentsinanacademiccenterinquebeccanada AT geraldbatist realworldoutcomesofincurablecancerpatientstreatedwithunlistedanticancertreatmentsinanacademiccenterinquebeccanada |